Prestige Consumer Healthcare Inc. 8-K

What Happened
Prestige Consumer Healthcare Inc. (PBH) filed an 8-K reporting that on July 1, 2026 it amended its Term Loan Credit Agreement to permit up to $95.0 million of additional term loans and borrowed $95.0 million under that amendment to finance the previously announced acquisition of LaCorium Health Australia and related fees and expenses. The Company also disclosed a private offering process for $400.0 million of senior unsecured notes due 2034 (announcement June 30, 2026) and on July 6, 2026 issued a press release announcing the closing of the LaCorium acquisition and the pricing of the notes.

Key Details

• Amendment to Term Loan Credit Agreement effective July 1, 2026 allows up to $95.0 million of additional term loans.
• Prestige Brands, Inc. (the Company’s wholly-owned borrower subsidiary) drew $95.0 million on July 1, 2026 to fund the LaCorium Acquisition.
• The Company commenced a private offering of $400.0 million aggregate principal amount of senior unsecured notes due 2034 (press release June 30, 2026) and announced note pricing and the acquisition closing on July 6, 2026.
• Administrative agent and lenders on the term loan include Citibank, N.A.; joint lead arrangers/bookrunners include Citibank, Barclays, Morgan Stanley, Goldman Sachs Bank USA and RBC Capital Markets.

Why It Matters
These actions increase Prestige’s outstanding debt and change its capital structure: a $95.0 million term-loan draw was used to close the LaCorium acquisition, and the company is issuing $400.0 million of unsecured notes due 2034. For investors, that means monitoring updated leverage, interest expense and liquidity metrics when Prestige reports its next periodic filings (the 10-Q will include the amendment as an exhibit). The filings confirm the company completed the targeted acquisition and established financing to support the transaction.